Skip to main content

Advertisement

SpringerLink
Log in

Reporting regression with melanoma in situ: reappraisal of a potential paradox

  • Review
  • Published:
Archives of Dermatological Research Aims and scope Submit manuscript

Abstract

Melanoma in situ (MIS) is a form of radial growth phase melanoma in which the proliferation of malignant cells is confined to the epidermis. Histologic features are invaluable in recognition of MIS. Regression occurs when the host’s immune system attacks the primary melanocytic tumor cells via tumor infiltrate lymphocytes, resulting in a fibrotic component. Various criteria have been proposed to assess the extent of histologic regression. Some authors define regression based on histologic features of the dermis, which is inappropriate for MIS. Specific dermatoscopic findings of regression in MIS have been reported including peppering, grey–blue areas, white areas, and blue-whitish veils. Many studies assess the impact of histologic regression on invasive melanoma prognosis, but no studies to-date have considered the effect of histologic regression exclusively in patients with MIS. The literature to-date does not suggest evaluation and management should be modified if histologic regression is present in MIS. Studies specifically investigating the effect of histologic regression on MIS prognosis are needed to inform evidence-based practices.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Aung PP, Nagarajan P, Prieto VG (2017) Regression in primary cutaneous melanoma: etiopathogenesis and clinical significance. Lab Investig 97:657–668. https://doi.org/10.1038/labinvest.2017.8

    Article  Google Scholar 

  2. Gershenwald JE, Scolyer RA (2018) Melanoma staging: American Joint Committee on Cancer (AJCC) 8th edition and beyond. Ann Surg Oncol 25:2105–2110

    Article  Google Scholar 

  3. Siegel RL, Miller KD, Jemal A (2020) Cancer statistics, 2020. CA Cancer J Clin 70:7–30. https://doi.org/10.3322/caac.21590

    Article  Google Scholar 

  4. Higgins HW, Lee KC, Galan A, Leffell DJ (2015) Melanoma in situ: part I. Epidemiology, screening, and clinical features. J Am Acad Dermatol 73:181–190

    Article  Google Scholar 

  5. Nikolaou V, Stratigos AJ (2014) Emerging trends in the epidemiology of melanoma. Br J Dermatol 170:11–19. https://doi.org/10.1111/bjd.12492

    Article  CAS  PubMed  Google Scholar 

  6. Swetter SM, Tsao H, Bichakjian CK et al (2019) Guidelines of care for the management of primary cutaneous melanoma. J Am Acad Dermatol 80:208–250. https://doi.org/10.1016/j.jaad.2018.08.055

    Article  PubMed  Google Scholar 

  7. Ehrsam E, Kallini JR, Lebas D et al (2016) Fully regressive melanoma a case without metastasis. J Clin Aesthet Dermatol 9:42–46

    PubMed  PubMed Central  Google Scholar 

  8. Ribero S, Moscarella E, Ferrara G et al (2016) Regression in cutaneous melanoma: a comprehensive review from diagnosis to prognosis. J Eur Acad Dermatology Venereol 30:2030–2037

    Article  CAS  Google Scholar 

  9. Guitart J, Lowe L, Piepkorn M et al (2002) Histological characteristics of metastasizing thin melanomas: a case-control study of 43 cases. Arch Dermatol 138:603–608. https://doi.org/10.1001/archderm.138.5.603

    Article  PubMed  Google Scholar 

  10. Higgins HW, Lee KC, Galan A, Leffell DJ (2015) Melanoma in situ: Part II. Histopathology, treatment, and clinical management. J Am Acad Dermatol 73:193–203. https://doi.org/10.1016/j.jaad.2015.03.057

    Article  PubMed  Google Scholar 

  11. Linos E, Swetter SM, Cockburn MG et al (2009) Increasing burden of melanoma in the United States. J Invest Dermatol 129:1666–1674. https://doi.org/10.1038/jid.2008.423

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Welch HG, Woloshin S, Schwartz LM (2005) Skin biopsy rates and incidence of melanoma: population based ecological study. BMJ 331:481. https://doi.org/10.1136/bmj.38516.649537.E0

    Article  PubMed  PubMed Central  Google Scholar 

  13. Mocellin S, Nitti D (2011) Cutaneous melanoma in situ: translational evidence from a large population-based study. Oncologist 16:896–903. https://doi.org/10.1634/theoncologist.2010-0340

    Article  PubMed  PubMed Central  Google Scholar 

  14. Mu EW, Quatrano NA, Yagerman SE et al (2018) Evaluation of MITF, SOX10, MART-1, and R21 immunostaining for the diagnosis of residual melanoma in situ on chronically sun-damaged skin. Dermatol Surg 44:933–938. https://doi.org/10.1097/DSS.0000000000001493

    Article  CAS  PubMed  Google Scholar 

  15. Bartoli C, Bono A, Clemente C et al (1996) Clinical diagnosis and therapy of cutaneous melanoma in situ. Cancer 77:888–892. https://doi.org/10.1002/(sici)1097-0142(19960301)77:5<888:aid-cncr12>3.0.co;2-#

    Article  CAS  PubMed  Google Scholar 

  16. Lallas A, Longo C, Manfredini M et al (2018) Accuracy of DERMOSCOPIC CRITERIA FOR THE DIAGNOSIS OF MELANOMA IN SITu. JAMA Dermatol 154:414–419. https://doi.org/10.1001/jamadermatol.2017.6447

    Article  PubMed  PubMed Central  Google Scholar 

  17. Seidenari S, Bassoli S, Borsari S et al (2012) Variegated dermoscopy of in situ melanoma. Dermatology 224:262–270. https://doi.org/10.1159/000338696

    Article  PubMed  Google Scholar 

  18. Seidenari S, Ferrari C, Borsari S et al (2010) Reticular grey-blue areas of regression as a dermoscopic marker of melanoma in situ. Br J Dermatol 163:302–309. https://doi.org/10.1111/j.1365-2133.2010.09821.x

    Article  CAS  PubMed  Google Scholar 

  19. Ribero S, Galli F, Osella-Abate S et al (2019) Prognostic impact of regression in patients with primary cutaneous melanoma >1 mm in thickness. J Am Acad Dermatol 80:99–105.e5. https://doi.org/10.1016/j.jaad.2018.06.054

    Article  PubMed  Google Scholar 

  20. Shai A, Avinoach I, Sagi A (1994) Metastatic malignant melanoma with spontaneous and complete regression of the primary lesion. Case report and review of the literature. J Dermatol Surg Oncol 20:342–345. https://doi.org/10.1111/j.1524-4725.1994.tb01635.x

    Article  CAS  PubMed  Google Scholar 

  21. Smoller BR (2006) Histologic criteria for diagnosing primary cutaneous malignant melanoma. Mod Pathol 19(Suppl 2):S34–40. https://doi.org/10.1038/modpathol.3800508

    Article  PubMed  Google Scholar 

  22. Zurac S, Neagu M, Constantin C et al (2016) Variations in the expression of TIMP1, TIMP2 and TIMP3 in cutaneous melanoma with regression and their possible function as prognostic predictors. Oncol Lett 11:3354–3360. https://doi.org/10.3892/ol.2016.4391

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Kang S, Barnhill RL, Mihm MCJ, Sober AJ (1993) Histologic regression in malignant melanoma: an interobserver concordance study. J Cutan Pathol 20:126–129. https://doi.org/10.1111/j.1600-0560.1993.tb00228.x

    Article  CAS  PubMed  Google Scholar 

  24. Bassoli S, Borsari S, Ferrari C et al (2011) Grey-blue regression in melanoma in situ—evaluation on 111 cases. J Skin Cancer 2011:1–5. https://doi.org/10.1155/2011/180980

    Article  Google Scholar 

  25. Alarcon I, Carrera C, Palou J et al (2014) Impact of in vivo reflectance confocal microscopy on the number needed to treat melanoma in doubtful lesions. Br J Dermatol 170:802–808. https://doi.org/10.1111/bjd.12678

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  26. Mikkelsen J, Hagen Wagenblast AL, Behrendt N, Lock-Andersen J (2017) Melanoma in situ with in-transit metastases. JPRAS Open 11:37–42. https://doi.org/10.1016/j.jpra.2017.01.006

    Article  Google Scholar 

  27. Sun SH, Peters SB, Howard JH (2017) Sentinel lymph node melanosis: a report of two cases of regressed melanoma metastases. SM Dermatol J 3:1–3. https://doi.org/10.36876/smdj.1014

    Article  Google Scholar 

  28. Zugna D, Senetta R, Osella-Abate S et al (2018) Favourable prognostic role of histological regression in stage III positive sentinel lymph node melanoma patients. Br J Cancer 118:398–404. https://doi.org/10.1038/bjc.2017.397

    Article  CAS  PubMed  Google Scholar 

Download references

Funding

No funding was received.

Author information

Authors and Affiliations

  1. University of Maryland School of Medicine, Baltimore, MD, USA

    Alexander M. Cartron & Paola C. Aldana

  2. Veterans Affairs Medical Center, Brooklyn, NY, USA

    Amor Khachemoune

  3. Department of Dermatology, SUNY Downstate, Brooklyn, NY, USA

    Amor Khachemoune

  4. Veterans Affairs Hospital and SUNY Downstate Dermatology Service, 800 Poly Place, Brooklyn, NY, 11209, USA

    Amor Khachemoune

Authors
  1. Alexander M. Cartron
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Paola C. Aldana
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Amor Khachemoune
    View author publications

    You can also search for this author in PubMed Google Scholar

Contributions

AK had the idea for the article. AMC performed the initial literature search and data analysis. AMC drafted the initial draft. PCA performed an additional literature search and secondary data analysis. PCA and AK revised the work.

Corresponding author

Correspondence to Amor Khachemoune.

Ethics declarations

Conflicts of interest

Alexander M. Cartron, BS, Paola C. Aldana, MD, and Amor Khachemoune, MD, FAAD, FACMS declare that they have no potential conflicts of interest to disclose.

Ethical approval

Not applicable.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

This article contains original unpublished work that is not being submitted for publication or presentation elsewhere.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Cartron, A.M., Aldana, P.C. & Khachemoune, A. Reporting regression with melanoma in situ: reappraisal of a potential paradox. Arch Dermatol Res 313, 65–69 (2021). https://doi.org/10.1007/s00403-020-02106-w

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00403-020-02106-w

Keywords

Search

Navigation